SIVEXTRO
Peaktedizolid phosphate
NDAORALTABLETPriority Review
Approved
Jun 2014
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
12
Clinical Trials (5)
A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)
Started Jul 2024
18 enrolled
Healthy
A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)
Started Mar 2022
36 enrolled
Healthy
A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)
Started Feb 2019
47 enrolled
Gram-Positive Infections
A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)
Started Jan 2019
100 enrolled
Acute Bacterial Skin and Skin Structure Infections
Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study
Started Dec 2016
108 enrolled
Skin Disease, Infectious
Loss of Exclusivity
LOE Date
Dec 31, 2030
58 months away
Patent Expiry
Dec 31, 2030
Exclusivity Expiry
Apr 4, 2028